Novartis Stockpiling Priority Review Vouchers
Executive Summary
Firm picks up second PRV with purchase from Ultragenyx, which is expected to use the $130m to help advance its rare disease development pipeline.
You may also be interested in...
Novartis Secures FDA Priority Review For Brolucizumab Thanks To PRV
Novartis used a priority review voucher for brolucizumab, positioning the eye drug for a US launch in late 2019 if the FDA review goes smoothly.
Ultragenyx Gets Second Drug Approval; Crysvita With Kyowa Hakko Kirin
Ultragenyx already has a sales team in place to market its second commercial drug Crysvita (burosumab) – partnered with Kyowa Hakko Kirin – following its April 17 FDA approval for the treatment of pediatric and adult patients with x-linked hypophosphatemia (XLH).
Spark's Luxturna Approval Ushers In A New Gene Therapy Era
Spark's gene therapy for patients with an inherited form of blindness will be available in the US late in the first quarter, but on the big question – whether it will cost $1m for the one-time treatment – Spark would not say.